Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=434	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=435	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=436	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=437
HGNC, UniProt	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6264, http://www.uniprot.org/uniprot/P48549	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6267, http://www.uniprot.org/uniprot/P48051	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6270, http://www.uniprot.org/uniprot/Q92806	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6266, http://www.uniprot.org/uniprot/P48544
Endogenous activators	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387 (Agonist) (pK d 6.3) Concentration range: 5×10−5M [physiological voltage] [http://www.ncbi.nlm.nih.gov/pubmed/9486652?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387 (Agonist) (pK d 6.3) Concentration range: 5×10−5M [physiological voltage] [http://www.ncbi.nlm.nih.gov/pubmed/9486652?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387 [http://www.ncbi.nlm.nih.gov/pubmed/8688080?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387 [http://www.ncbi.nlm.nih.gov/pubmed/9804555?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8688080?dopt=AbstractPlus]
Gating inhibitors	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90 (Antagonist) (pEC50 5.5) [‐70mV] [http://www.ncbi.nlm.nih.gov/pubmed/10780978?dopt=AbstractPlus] – Mouse	–	–
Endogenous channel blockers	–	–
Channel blockers	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2383 (Antagonist) (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/10572004?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2344 (Antagonist) (pIC50 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/8234283?dopt=AbstractPlus] – Rat	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2399 (Antagonist) (pIC50 4.4) [‐70mV] [http://www.ncbi.nlm.nih.gov/pubmed/15150531?dopt=AbstractPlus] – Mouse	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2383 (Antagonist) (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/10572004?dopt=AbstractPlus]
Functional Characteristics	G protein‐activated inward‐rectifier current	G protein‐activated inward‐rectifier current	G protein‐activated inward‐rectifier current	G protein‐activated inward‐rectifier current
Comments	Kir3.1 is also activated by Gβγ. Kir3.1 is not functional alone. The functional expression of Kir3.1 in Xenopus oocytes requires coassembly with the endogenous Xenopus Kir3.5 subunit. The major functional assembly in the heart is the Kir3.1/3.4 heteromultimer, while in the brain it is Kir3.1/3.2, Kir3.1/3.3 and Kir3.2/3.3.	Kir3.2 is also activated by Gβγ. Kir3.2 forms functional heteromers with Kir3.1/3.3.	Kir3.3 is also activated by Gβγ	Kir3.4 is also activated by Gβγ